Sanofi
13F holdings for Q2 2026 · Paris, I0 · filed July 28, 2026
Sanofi reported $534M in 13F securities across 10 holdings for Q2 2026, in a Form 13F filed July 28, 2026. The largest positions were Meiragtx Holdings PLC (30.9%), INBX (20.5%), NVAX (12.1%). Reported value rose 59.0% from the quarter before. It opened 2 new positions, added to 0, trimmed 0 and sold out of 1.
- 13F value Q2 2026
- $534M
- Holdings
- 10
- Change vs prior quarter
- +59.0%
- Rank by 13F value
- #3,714
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Top holdings
| Stock | Value | Weight | Shares | Change in shares | Move |
|---|---|---|---|---|---|
| Meiragtx Holdings PLC | $165M | 30.9% | 12,197,737 | 0% | Unchanged |
| INBX Inhibrx Biosciences Inc. | $110M | 20.5% | 1,157,926 | 0% | Unchanged |
| NVAX Novavax Inc. | $64.8M | 12.1% | 6,880,481 | 0% | Unchanged |
| ANAB AnaptysBio Inc. | $55.5M | 10.4% | 821,917 | 0% | Unchanged |
| ODTX Odyssey Therapeutics Inc. | $37.3M | 7.0% | 1,991,918 | New | New |
| AGMB AgomAb Therapeutics NV | $36.1M | 6.8% | 2,783,096 | 0% | Unchanged |
| MPLT MapLight Therapeutics Inc. | $32.7M | 6.1% | 912,041 | 0% | Unchanged |
| TRAX First Tracks Biotherapeutics Inc. | $16.5M | 3.1% | 821,917 | New | New |
| IMRX Immuneering Corporation | $13.5M | 2.5% | 2,708,559 | 0% | Unchanged |
| QTTB Q32 Bio Inc. | $3.1M | 0.6% | 244,083 | 0% | Unchanged |
Share positions only, at the value reported for the end of Q2 2026. Weight is the share of $534M in share positions; options and bonds count in the 13F value but not here.
Biggest buys in Q2 2026
- ODTX Odyssey Therapeutics Inc. New+$37.3M
- TRAX First Tracks Biotherapeutics Inc. New+$16.5M
Biggest sells in Q2 2026
- ELDN Eledon Pharmaceuticals Inc. Sold out-$2.5M
The change in shares since Q1 2026, adjusted for stock splits and priced at the Q2 2026 value per share. 2 new, 0 added, 0 trimmed, 1 sold out.
Sector mix
- Health Care69.1%
- Not listed with us30.9%
13F value by quarter
Schedule 13D and 13G filings by Sanofi
Stakes above 5% of a company, filed within days rather than once a quarter.
- 2026-05-06AGMB SCHEDULE 13G filed by AgomAb Therapeutics NVSchedule 13G
- 2025-04-29IPHA SCHEDULE 13G filed by Innate Pharma S.A. ADSSchedule 13G
Questions about Sanofi
- What does Sanofi own?
- In its Form 13F for Q2 2026, Sanofi reported 10 holdings worth $534M. The five largest were Meiragtx Holdings PLC, INBX, NVAX, ANAB, ODTX.
- What did Sanofi buy and sell in Q2 2026?
- Sanofi opened 2 new positions, added to 0, trimmed 0 and sold out of 1 compared with the quarter before.
- When did Sanofi file its latest 13F?
- Form 13F is due 45 days after each quarter ends. The Q2 2026 report was due August 14, 2026 and was filed July 28, 2026.
From Form 13F filed by Sanofi (SEC CIK 0001121404) for the quarter ended June 30, 2026, via the SEC's Form 13F data sets. Amendments that restate a report replace it; amendments that add holdings are included. View on SEC EDGAR · All funds